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Breast conservation therapy (BCT), which is the marriage of breast conserving surgery and radiation therapy to the breast, has
revolutionized the treatment of breast cancer over the last few decades. Surgical direction had seen a heightened interest in the
performance of cosmetically superior partial and segmental resections in breast conservation as well as increased demand by
patients for breast preservation. The broadening of approaches to delivery of breast irradiation from whole breast to accelerated
partial breast has allowed more patients to opt for breast conservation and allowed for what appears to be comparable measurable
outcomes in emerging data. As well, the addition of state-of-the-art chemotherapeutic and hormonal therapies has allowed
improved outcomes of patients from both local regional recurrence and overall survival standpoints. This paper will provide
an overview of BCT and review some of the newest developments in optimizing this therapy for patients with breast cancer from
a surgical-, medical-, and radiation-oncology standpoint.
1.SurgicalPerspective
1.1. Introduction. Much has changed in the management of
breast cancer especially over the last few decades. The shift
from the Halstedian radical mastectomy (Figure 1)t oB C T
serves as a remarkable example of the advances in surgical
care of the breast cancer patient. The Breast conservation
has improved the quality of life for many patients in terms
of retention of body image and overall decreased physical
morbidity (Figure 2). The Data also support that BCT
aﬀordspatients’thesameoverallsurvivalwithoutstatistically
signiﬁcant increased local recurrence rates [1–5]. The con-
tinued success of BCT has evolved from advances in surgical
techniques and pathologic analyses with the application of
state-of-the-art radiation and chemotherapeutic regimens.
1.2. Brief History of Surgery for Breast Cancer. Ab r i e ft o u r
through the history of surgical therapy of breast cancer is
warranted to better put into context the treatment of breast
cancer as we know it today. In the late 19th century, Halstead
popularized the radical mastectomy [6, 7]. This surgical
approach involved en bloc resection of the aﬀected breast,
overlying skin, pectoral muscles, and axillary lymphadenec-
tomy. At the time, this extensive procedure was performed
to gain local-regional control of disease that was thought
to primarily spread in a stepwise fashion from the breast
through lymphatics to the lymph nodes, where it remained
latent before spreading to distant organs. The patients of
this time typically presented with locally advanced disease
or neglected disease that in many respects justiﬁed such a
radical approach. Ironically, women of the time, knowing
what awaited them surgically should they be diagnosed with
breast cancer, might be known to delay seeking medical care,
laying the ground work for a surgical self-fulﬁlling prophecy
of sorts [8].
Geoﬀr e yK e y n e sr e p o r t e di nt h ee a r l y2 0 t hc e n t u r ye q u a l
resultsoflocalbreasttumorexcisionwithradiumirradiation
to traditional Halstedian radical mastectomy (RM) [8].
Despite this, the practice of RM continued for decades to
follow. With time, the RM approach fell out of favor as it
became recognized that patient-treatment failure was due to
systemic spread of disease prior to surgery and not due to
inadequate surgery. The emergence of the modiﬁed radical
mastectomy (MRM), which involves removal of the breast
and typically Level I and II nodal basins, was then seen.2 ISRN Oncology
(a) (b)
Figure 1: This patient serves as a reminder of the physical deformity (a) and morbidity associated with the Halstedian radical mastectomy.
Note the compression sleeve for control of lymphedema and the decreased range of motion of the patient’s left arm (b).
(a) (b)
Figure 2: These patients are examples of the retention of body image with breast conservation surgery.
More and more patients by the 1970s were presenting with
smaller tumors not ﬁxed to the underlying pectoral muscle,
which made adoption of MRM a natural choice. As well,
bothretrospectiveandprospectivestudiesofthistimeperiod
revealed no diﬀerence between MRM and RM in terms of
patient survival [9–12].
Following this, multiple prospective randomized trials
demonstrated that patient survival after undergoing BCT
(consisting of local tumor excision, axillary dissection, and
whole breast irradiation) was equivalent to mastectomy in
the treatment of invasive breast cancer [1–5].
With the advent of sentinel lymph node biopsy (SLNB),
more patients are undergoing BCT or mastectomy with this
targeted axillary lymph node sampling, which has decreased
patientmorbidityintermsofrangeofmotionofthearmand
lymphedema. Three-year followup data from the NSABP B-
32 study concluded a superiority of SLNB to axillary nodal
dissection when it came to postsurgical morbidity outcomes
[13].
1.3.BreastConservationSurgery. Forpatientstobeneﬁtfrom
BCT, it must ﬁrst be oﬀered and delivered to them by the
surgeon. Despite the decades of work and research dedicated
to establishing the equivalence of BCT to mastectomy in the
treatment of breast cancer, there remain a disproportionately
lower number of women undergoing BCT as compared
to mastectomy for disease processes that are otherwise
amenable to conservation techniques. In 1990, a National
Institutes of Health Consensus Development Conference on
the treatment of patients with early stage invasive breast
cancer recommended breast conservation for the majority
of women with Stage I and II diseases. Even after that
conference, it was noted at the time that although BCT
was performed more often than previously, there were still
barriers that existed to the widespread adoption of the
treatment [14]. Fast forward to more present time and there
is still documented underutilization of BCT for appropriate
candidates with numerous studies dissecting the possible
reasons for this practice [15–20].ISRN Oncology 3
In assessing a patient for candidacy for breast con-
servation, there are psychosocial aspects that need to be
considered as well as medical aspects. From a psychosocial
aspect, there is no question that counseling of patients to
their options is a time-intensive endeavor and can be very
emotionally charged as the patient is faced not only with a
new diagnosis of cancer but is faced with multiple decision
trees that ultimately aﬀect her body image, her thoughts on
her own mortality, and her social-, work-, and family-life.
From a medical perspective, patients that are best suited
for BCT are those with solitary, primary breast lesions
whose surgery can achieve negative microscopic margins,
and are medically suitable for chest wall irradiation. When
considering the patient’s case for BCT versus mastectomy,
the practitioner must take into account tumor to breast size
ratio, multicentricity, tumor characteristics such as extensive
mammographic calciﬁcations, technical ability to clear mar-
gins, and any contraindications for radiation therapy [21].
For example, if a patient has a relatively small breast size with
a large area of microcalciﬁcations, she may not prove to be
the best candidate for conservation, lest inadequate margin
clearance or poor cosmetic outcome results. However, in
cases where the patient has a relatively small breast size
in relation to a tumor mass, neoadjuvant chemotherapy
may provide an avenue for tumor size reduction and
ultimate successful breast conservation surgery. In general,
the performance of breast conservation therapy in early
stage disease is not limited by tumor size (except as noted
above), tumor type, nodal status, or biologic characteristics
of the tumor. Even with this latitude for eﬀective surgery,
there still exists some surgeon bias as noted by Keating et
al. where only 71% of women reported that their surgeon
discussed both BCT and mastectomy with them [22].
Others have reported surgeon bias as a driving force to the
performance of mastectomy to BCT. One study surveyed
surgeons regarding the management of T1 tumors and 56%
of the group indicated that they did not believe mastectomy
and BCT were equal treatment options or that they biased
their discussions with patients in favor of mastectomy [23].
Morrow et al. showed that medical contraindications to BCT
were not a major factor in the execution of BCT in their
institution. They implemented a multidisciplinary approach
to patient management with a standard set of criteria for
BCT eligibility, which they felt minimized confusion about
which patients were candidates for BCT. This points more
to other potential factors such as surgeon bias as inﬂuencing
patient choice of BCT versus mastectomy. They suggest that
changes in surgeon attitude and continuing education about
patient selection may do more to increase the utilization of
BCT [24].
Simplistically put, breast conservation therapy oﬀers
patients retention of body habitus most closely to the natural
state, although surgical alterations of the breast, especially
with the addition of radiation, can often lead to suboptimal
cosmetic outcomes [25]. Wang et al. reported that 28% of
BCT in their series were dissatisﬁed with their cosmetic
outcome and this group was more likely to have a negative
change in their body image when compared with patients
who were satisﬁed with their cosmetic result. They also
reported that age younger than 52 years and the resection
from the upper inner quadrant from the breast were risk
factors predicting patient dissatisfaction [26].
Although there are many patients who experience good,
primary cosmetic outcomes with BCT, there is emerging
literature on the concept of oncoplastic breast conservation
surgery for patients with suboptimal cosmetic outcomes.
This concept has been widely published on in the last
few years [27–30] and involves a one-stage combined
approach by the oncologic and reconstructive surgeons,
whereby reconstruction of the conserved breast is performed
with a volume-displacing procedure involving local tissue
reshaping and rearrangement by reduction mammoplasty
or mastopexy to ﬁll in the dead space created by tumor
resection [27]. Meretoja et al. reported on their small series
of 15 patients undergoing oncoplastic surgery post-breast
conservation where 84% of patients had negative margins
andacceptablecosmeticresults[29].InalargerseriesbyBong
et al., the authors report on 167 patients who underwent
oncoplastic mastopexy reconstruction after breast conserva-
tionsurgery.Intheirseries,theydemonstratedtheutilityand
adequacy of oncoplastic techniques when addressing larger
ordiﬃcultlypositionedtumorsforbreastconservation.They
showed that margin positivity could be addressed easily by
directed, single-face excision without substantially aﬀecting
cosmesis [31].
Despite the challenges that exist with the broader appli-
cation of BCT, it is likely that as patients are more and
more exposed to the information highway and have access
to medical data at their ﬁngertips, their demand for optimal
surgical management will increase. And as Melvin Silverstein
sites in reference to oncoplastic techniques, which can be
just as appropriately said about BCT, “it will soon become
patient driven and demanded. If surgeons do not oﬀer it,
their patients will drift away to surgeons who do” [28].
2.MedicalOncology Perspective
2.1. Neoadjuvant Systemic Therapy. In treating operable and
locally advanced breast cancer, the clinician hopes to achieve
three primary aims:
(1) Eradication of disease (cure),
(2) Minimization of morbidity,
(3) Acceptable cosmesis.
Increasing acceptance of neoadjuvant systemic therapy
(NST) as a standard of care has evolved as trials have
established both eﬃcacy and increased breast conservation
rates with this approach. Additional beneﬁts, including the
prognostic value of NST response and individualized NST
approaches based on tumor characteristics are likely to alter
care delivery in the near future.
Neoadjuvant therapy was initially described as a single
modality (chemotherapy) for a limited indication (locally
advanced or inﬂammatory tumors) [32]. Recent advances,
detailed below, have broadened the deﬁnition of NST
to include chemotherapy, endocrine therapy, and targeted4 ISRN Oncology
therapy, and expanded the indications to include Stage I–III
breast cancers.
2.2. Eﬃcacy of NST. NST oﬀers a number of theoretical
advantagesoverconventionaladjuvanttherapy,andthereare
hypothetical disadvantages worth noting as well (Table 1).
Hypotheses notwithstanding, now that a number of NST
trials have been completed, some reliable paradigms have
emerged (1) in terms of disease-free and overall survival,
neoadjuvant chemotherapy is equivalent to traditional adju-
vant chemotherapy, (2) NST results in higher rates of
BCS as compared to identical postoperative treatment, (3)
response to NST provides valuable prognostic information,
and (4) NST provides an excellent platform to conduct novel
biomarker-driven studies with the aim of advancing the
standard of care.
Two landmark neoadjuvant chemotherapy (NCT) tri-
als recently reported long-term followup data. EORTC
10902 and NSABP B-18 randomized patients with operable
breast cancer to receive pre- or postoperative anthracy-
cline/cyclophosphamide × 4 cycles. With 10 and 16 years of
followup, respectively, there was no diﬀerence in the primary
endpoints of disease-free survival (DFS) or overall survival
(OS) in either study [33, 34]. Meta-analyses also conﬁrm
equivalenceofpreoperativeandpostoperativechemotherapy
for endpoints of death (summary RR 1.00, 95% CI = 0.90–
1.12), disease progression (summary RR 0.99, 95% CI =
0.91–1.07), and distant disease recurrence (RR 0.94, 95%
CI = 0.83–1.06) [35, 36]. In regards to overall antineoplastic
eﬀect, these data suggest that survival depends more on
intrinsic biologic factors of the primary tumor itself rather
than the timing of chemotherapy (before or after surgery).
One potential caveat regarding NCT was raised in these
early trials. In NSABP B-18, there was a nonsigniﬁcant
trend towards increased ipsilateral breast tumor recurrence
(IBTR),13%intheNSTarmversus10%intheadjuvantarm
[34]. In the Mauri meta-analysis, NCT was associated with
a statistically signiﬁcant increase in locoregional recurrence
(LRR) (RR 1.22, 95% CI = 1.04–1.43), although this was
primarily due to inclusion of trials in which patients were
treated with NCT and radiation therapy alone, omitting
surgery [35].
A retrospective analysis of 340 patients treated with NCT
at MD Anderson identiﬁed an IBTR rate of 5% and LRR
rateof 9%, comparableto IBTR/LRRrates with conventional
postoperativetherapy[37].FeaturesassociatedwithLRRrisk
included cN2/N3 disease, lymphovascular space invasion,
residual disease >2cm in size, and a multifocal pattern
of residual disease. These features were later incorporated
into a prognostic index to help identify patients at higher
r i s kf o rL R Ra f t e rN C T[ 38]. In general, patients with
the following features after NCT should not be oﬀered
BCT:skininvolvement/edema,residualtumor>5cm,diﬀuse
calciﬁcations, residual multicentric disease, or inability to
receive adjuvant radiotherapy.
2.3. Increased BCT Rates. Clinical response to NCT corre-
lates with tumor downstaging and increased rates of BCT. In
Table 1: Hypothetical advantages/disadvantages of NST. Only one
hypothesis (in bold) is corroborated by current data.
Advantages Disadvantages
Delivery of systemic therapy
via intact tumor vasculature Inaccurate post-NST staging
In vivo response assessment
with potential to tailor
therapy accordingly
Treatment of larger overall
tumor burden
Earlier treatment of
micrometastatic disease Delay in curative local therapy
Potential to downstageand
facilitate BCT
Increased risk for
surgical/radiation
complications
NSABP B-18, there was a statistically signiﬁcant diﬀerence
in frequency of BCT for patients in the NCT group (67%
versus 60%, P = .002) [34]. In EORTC 10902, there was
also a statistically signiﬁcant diﬀerence in BCT rates (35%
versus22%)[33].Interestingly,BCTratesacrossanumberof
NCT trials vary dramatically, ranging between 13 and 83%,
reﬂecting diﬀerences in inclusion criteria, NCT regimen,
patient preference, and surgeon practice. Taken together,
these data have established that NCT can allow for BCT in a
signiﬁcant proportion of patients for whom mastectomy was
the initially preferred option.
2.4. Prognostic Relevance of Response to NCT. Degree of
response to NCT positively correlates with overall and
disease-free survival. In NSABP B-18, patients who achieved
pathologic complete response (pCR) had better OS at 16
years of followup (83.7% versus 55.7%, HR = 0.32, P<
.00001). Similar results were seen in NSABP B-27, with OS at
8 years favoring those achieving pCR (89.4% versus 73.6%,
HR = 0.36, P<. 00001) [34].
Variation in the deﬁnition of pCR has limited compari-
sonacrossstudies,promptingthedevelopmentofanalterna-
tive measurement index, residual cancer burden (RCB) [39].
The RCB is derived from measurements of residual primary
tumor, cellularity of the tumor bed, and axillary nodal
burden, and therefore more accurately reﬂects the broad
spectrum of residual disease encountered in clinical practice.
The RCB is grouped into four categories (RCB 0, I, II, III),
with RCB 0 being equivalent to pCR and the other three
categories representing increasing levels of residual disease.
In a validation study, patients with RCB 0 or RCB I had
similar DFS, suggesting that near-pCR may be prognostically
equivalent to pCR. Moreover, the RCB stratiﬁed prognosis
within posttreatment AJCC stages (“y” stage), providing
valuable prognostic information for progressive levels of
residual disease.
2.5. Development of Current Standards. As in the adjuvant
setting, no “optimal” neoadjuvant chemotherapy regimen
has been deﬁned. There are now a number of eﬀective
options from which to choose and, in general, consensus
guidelinessuggestthatregimensrecommendedforuseintheISRN Oncology 5
adjuvant setting are appropriate for use in the neoadjuvant
setting [40].
The incorporation of taxanes into NCT results in signif-
icant improvement in pCR rates. In NSABP B-27, patients
received neoadjuvant AC (4 cycles) and were subsequently
randomized to receive no further chemotherapy, neoadju-
vant docetaxel (4 cycles), or adjuvant docetaxel (4 cycles).
Patients in the neoadjuvant docetaxel arm experienced twice
as many pCRs (26% versus 13%, P<. 001), but no beneﬁt in
D F So rO Sw a sd e m o n s t r a t e d[ 34]. The Geparduo trial con-
ﬁrmed that sequential administration of anthracycline and
taxaneismoreeﬀectivethanconcurrentadministration[41].
For patients with Her2-positive disease, the addition of
trastuzumab to standard NCT results in dramatic improve-
ment in pCR and DFS rates. Buzdar et al. reported an
increase in pCR rate from 26.3% to 65.2% (P = .016) in
patients receiving NCT versus NCT plus trastuzumab [42].
Similar results were seen in the NOAH trial, with improved
pCR rate (23% versus 43%, P = .002) and DFS rate (53.5%
versus 70.1%, P = .007) with addition of trastuzumab to
NCT [43]. Rates of clinically signiﬁcant cardiac dysfunction
were low in both studies. ACOSOG Z1041, currently accru-
ing, will deﬁnitively address the question of safety in regards
to coadministration of epirubicin with trastuzumab.
In general, choice of NCT regimen is determined largely
by tumor characteristics, patient factors, physician prefer-
ence, and institutional/regional trends. At MD Anderson,
for Her2-negative tumors, the standard NCT regimen is
weekly paclitaxel (12 doses) followed by FAC (4 cycles).
For Her2-positive tumors, the standard NCT regimen is
weekly paclitaxel-trastuzumab (12 doses) followed by FEC-
trastuzumab (4 cycles), with herceptin completed to 1-year
total postoperatively.
2.6. Modifying NCT Based on Response. One hypothetical
beneﬁt of NST is the ability to assess in vivo response and
adjust therapy to maximize response. Smith et al. examined
this issue by treating patients with 4 cycles of neoadjuvant
anthacycline-based chemotherapy. Responders were then
randomized to receive an additional 4 cycles of anthracycline
or 4 cycles of docetaxel, and nonresponders all received 4
cycles of docetaxel. Interestingly, responders preferentially
beneﬁtted from incorporation of docetaxel (pCR rate 30.8%
versus 15.4% in anthracycline-only group, P = 0.04),
whereas nonresponders derived essentially no beneﬁt (pCR
rate 1.8%) [44].
Similar ﬁndings were identiﬁed in the GEPARTRIO trial,
where patients received two cycles of neoadjuvant TAC
(docetaxel, doxorubicin, cyclophosphamide), with nonre-
sponders subsequently randomized to 4 additional cycles
of TAC versus 4 cycles of vinorelbine/capecitabine. No
diﬀerence was identiﬁed in the pCR rate (5.3% versus 6.0%)
[45].
Taken together, these data suggest that clinical nonre-
sponders may harbor tumors that are broadly chemore-
sistant. Further studies are needed to identify predictors
of chemoresistance as well as novel agents to reestablish
response in this population.
Table 2: Sorlie molecular subtypes and response to neoadjuvant
chemotherapy [50, 51, 59].
Sorlie subtype Receptor correlates Estimated pCR rates
Luminal A HR+, Her2− 7–12%
Luminal B HR+, Her2+ 15–25%
Her2-like HR−,H e r 2 + 20–25% (without Herceptin)
40–60% (with Herceptin)
Basal HR−,H e r 2 − 25–55%
2.7. Predictors of NST Response. Tumor histology may be
an important predictor of NST response. Across multiple
studies, pCR rates for invasive lobular carcinomas (ILC) are
in the 1–3% range, as opposed to pCR rates in the 15%
range for invasive ductal carcinomas (no special type) [46].
Comparing HR-positive ILC and IDC, pCR rates for ILC
remain relatively low (4% versus 9%, P = .03). Moreover,
BCS rates after NCT with ILC are lower than for IDC (16%
versus 29%, P = .003) [47]. Some authors have suggested
that ILC should not be treated with NCT [48], and this
remains an area of investigation.
ER/PR status independently predicts likelihood of
achieving pCR. In the ECTO trial, pCR rates were sig-
niﬁcantly lower for ER-positive versus ER-negative tumors
(12% versus 42%, P<. 0001) [49]. A larger retrospective
analysis from MD Anderson supports the conclusion that
HR-positive tumors have lower pCR rates (8% versus 24%,
P<. 0001) [50]. Importantly, although the odds of achieving
pCR are lower in HR-positive patients, the OS and PFS
beneﬁt of achieving pCR is retained. Tumor diﬀerentiation
and proliferation rate also correlates with response in a
similar fashion; favorable biologic markers such as lower
grade and low proliferation rate predict for lower pCR
rates. An integrated view of the histologic and molecular
predictors, including Her2/neu status, is provided by the
Sorlie classiﬁcation (Table 2)[ 51].
Whilethemajorityofdatahasexploredfactorspredictive
of tumor response to NST, fewer studies have examined
predictors of disease progression during NST. A recent
retrospective study from MD Anderson identiﬁed progres-
sive disease in only 3% of patients receiving neoadju-
vant chemotherapy. In these patients, multivariate analysis
identiﬁed African-American race, higher T stage, and ER
negativity as predictors of progression, with high tumor
grade, high Ki-67 score, and PR negativity also identiﬁed
on univariate analysis [52]. Interestingly, some of these
factors (HR negativity, high grade, high Ki-67) also predict
for higher pCR rates, suggesting that such tumors may
represent two pathologically similar but clinically distinct
subpopulations.
Work continues on molecular proﬁling assays to further
characterizetumorsubtypesandidentifypatientsmostlikely
to derive beneﬁt from NST.
2.8. Neoadjuvant Endocrine Therapy. HR-positive disease
comprises approximately 75% of breast cancer cases.
Two ﬁndings propelled interest in neoadjuvant endocrine6 ISRN Oncology
therapy: (1) the eﬃcacy of endocrine therapy in the adju-
vant setting and (2) lower pCR rates with neoadjuvant
chemotherapy in HR-positive, Her2-negative tumors.
In the past, neoadjuvant endocrine therapy was studied
primarily in older, frailer patients with HR-positive tumors.
More recently, three major studies established the utility of
neoadjuvant endocrine therapy in downstaging HR-positive
tumors and improving BCT rates. P024 randomized post-
menopausal women to letrozole or tamoxifen ×4 months
prior to surgery. Achievement of the primary endpoint
(clinical response by palpation) favored the letrozole arm
(55% versus 36%, P<. 001), as did rate of BCS (45% versus
35%, P = .002) [53]. Two other phase III trials demon-
strated trends favoring clinical response with anastrozole
over tamoxifen, and conﬁrmed higher rates of BCT with
anastrozole [54, 55].
Two published studies have compared neoadjuvant
chemotherapy with neoadjuvant endocrine therapy. These
were smaller trials but conﬁrmed that clinical response
rates were generally similar across groups, with the notable
exceptionofpremenopausalpatients,whoexperiencedlower
response rates with neoadjuvant endocrine therapy [56, 57].
An important feature across neoadjuvant endocrine trials
is that pCR rates are generally low (1–5%). Other markers,
such as Ki-67, may correlate better with long-term outcome
and have led to the creation of a novel index that combines
pre- and posttreatment tumor features intended to predict
recurrence risk and need for adjuvant chemotherapy [58].
Currently, neoadjuvant endocrine therapy is not rec-
ommended in premenopausal women. In postmenopausal
women with HR-positive, Her2-negative tumors, use of an
neoadjuvant aromatase inhibitor can be considered on an
individualized basis.
2.9. Future Directions. Breast conservation is an important
goal for many patients with operable and locally advanced
breast cancer. Recent advances in NST highlight the impor-
tance of a tailored approach based on tumor and patient
characteristics.Developingnovelapproachestoindividualize
NST and treat chemoresistant disease is likely to lead to
higher BCT rates and improved outcomes.
3.RadiationOncology Perspective
There have been signiﬁcant advances in radiation therapy
as an adjuvant for breast conserving surgery in the last
several years. The advances have been in both whole-breast
irradiation andpartial-breast irradiation. The improvements
have spanned from computer tomography (CT) imaging
for target deﬁnition to more advanced radiation treatment
planning software resulting in more homogeneous dose
distributions. The end result is less acute and late treatment
toxicity with improved cosmesis and at least equal treatment
eﬃcacycomparedtopreviousmethodsofradiationplanning
and treatment delivery.
3.1. Whole-Breast Radiation. Adjuvant radiation therapy
after breast conserving surgery (BCS) is recommended to
eradicate potential microscopic residual disease adjacent to
the original tumor site after segmental resection, which may
be present 30 to 40% of the time [60]. The majority of in-
breast recurrences after BCS are in the same quadrant as the
original primary tumor [61–63]. Therefore, it is important
to ensure adequate coverage of the remaining breast tissue
adjacent to the surgical bed. This can be achieved quite
well with whole-breast irradiation. The advent of computed
tomography (CT) simulation has allowed us to contour
the surgical lumpectomy cavity as well as visualize normal
structures such as heart and lung.
In the supine position, the patient can be positioned
comfortably on an angle board at a set angle in a custom-
designed cradle to reproduce her treatment position each
day. The ipsilateral arm is abducted and rotated above the
head, to keep it out of the radiation ﬁelds. The semireclined
position tends to be more comfortable for the patient,
minimizing the risk of patient motion during treatment. The
angle board can be ﬁxed to the treatment table to ensure
exact patient positioning during treatment. A cradle is then
made,customizedtothepatientandherpositiontomaintain
the patient’s upper body position in the same location each
day. The custom-made cradle is ﬁxed to the angle board.
In the CT simulator, radio-opaque wire can be placed to
localize the surgical lumpectomy scar as well as to deﬁne
preliminary ﬁeld borders. Then CT images at 2.5mm to
3mm slice thickness are obtained through the breast. With a
large-bore CT simulator, even patients who require bilateral
breast irradiation due to bilateral synchronous breast cancer
can be imaged with a single CT data set.
The CT data set is then transferred to 3D CT-based
treatment planning system. This allows the patient to
be discharged from the clinic, while the dosimetrist and
radiation oncologist can optimize the treatment for the
individual patient. The surgical cavity is outlined as well
as the heart, if treatment is to the left breast. Often times,
the surgeon has left surgical clips outlining the edges of
the lumpectomy cavity, further aiding in the targeting of
the surgical bed. Field gantry angles, collimation, beam
weightings, and energies are chosen to allow a homogenous
dose distribution throughout the breast while minimizing
“hot” and “cold” regions of dose. In addition, the volume of
lung included in the radiation treatment ﬁeld is evaluated.
In general, only a limited volume of lung is encompassed
in the tangential ﬁelds, just enough to ensure coverage of
the deep breast tissue toward the chest wall and accounting
for breathing during treatment, resulting in some breast
movement. With 3D visualization of the operative bed and
the rest of the breast, the medial and lateral tangential beams
can be custom-designed to ensure dosimetric coverage of the
targeted surgical bed and/or surgical clips and surrounding
breast tissue while allowing for potential daily setup errors
and patient motion during treatment.
Standard whole breast irradiation is 45–50Gy delivered
at 1.8–2.0Gy/fraction over 4.5–5 weeks followed by a boost
dose to the surgical bed and scar of 10–16Gy delivered
at 2Gy/fraction over 1–1.5 weeks. Total dose is 60–66Gy
over a course of 6–6.5 weeks. There is now also interest
in a hypofractionated course of whole breast irradiation,ISRN Oncology 7
delivering the treatment over 3-4 weeks, rather than over 6-
6.5 weeks. A randomized study by Whelan et al., reported
an equivalent outcome for tumor control and normal tissue
eﬀects at 10 years. In an exploratory subgroup analysis,
patients with high-grade tumors treated with the hypofrac-
tionated regimen had a higher incidence of local recurrence
than those treated with the standard fractionation whole-
breast irradiation regimen [64]. At The University of Texas
MD Anderson Cancer Center, we currently reserve the use
of the hypofractionated whole-breast irradiation regimen of
42.4Gy at 2.65Gy/fraction to postmenopausal women with
pT1, N0, M0 invasive breast cancer of low to intermediate
grade that is estrogen receptor positive. We often follow this
with a boost dose of 10Gy in four fractions to the surgical
bed and scar.
The use of 3D CT-based treatment planning has im-
provedthedosimetrichomogeneityandvisualizationofdose
exponentially over 2D treatment planning. The prescription
dose is speciﬁed to an isodose line, generally following along
the pectoralis muscle surface and encompassing the breast
tissue. Given the 3D CT data set, we are able to evaluate
the dose deposited in every area of the breast, not just in a
single plane at the midlevel of the breast, as was previously
thecase.Inaddition,dosecalculationsnowtakeintoaccount
the heterogeneity of the various tissues included within the
treatment ﬁeld, such as the breast parenchyma, rib, and lung.
We are able to optimize the tangential whole breast plans,
so that signiﬁcant volumes of breast tissue do not exceed
105% of the prescribed dose. This has been made possible
by sophisticated treatment planning software. The “ﬁeld-
in-ﬁeld” technique, also known as “ﬁeld-in-ﬁeld forward-
planned intensity modulated radiotherapy (FiF-IMRT)”
provides excellent dose homogeneity in all three dimensions
of the breast, as compared to plans generated in the 2D era
with wedges. This improved dose homogeneity also allows
for better dosimetric coverage of the breast and lumpectomy
cavity. The improved homogeneity reduces increased dose
deposits (“hot spots”) such as in the inframammary fold,
axilla, and narrow portion of the breast toward the nip-
ple/areolar complex. The end result is less acute and long-
term side eﬀects of radiation therapy, such as acute dermati-
tis, edema, hyperpigmentation, and chronic breast edema
[65]. Using this technique, one starts with an open tan-
gential beam arrangement. High-dose volumes (e.g., 115%,
110%, 105%) are sequentially blocked with custom multileaf
collimation, generating smaller ﬁeld segments within the
main medial and lateral open tangential ﬁelds. These smaller
ﬁeld segments can be delivered as separate treatment ﬁelds
(ﬁeld in ﬁeld) or as part of the original ﬁelds with a step-
and-shoot technique. A percentage of the overall planned
dose each day is delivered with these smaller ﬁelds within
the main open ﬁeld (Figure 3). In addition, the scattered
dose to the contralateral breast with the FiF-IMRT technique
is less than the dose delivered with a conventional wedge
technique[66].TheFiF-IMRTtechnique,thestep-and-shoot
forward-planned IMRT technique, and an inversely-planned
breast IMRT technique can all improve dose homogeneity
compared with a conventional wedge technique. For patients
with larger breast sizes and/or separation distances, higher
Max = 5254cGy
Figure 3: An example of a step and shoot forward-planned IMRT
breast treatment plan. Notice the very homogenous coverage of the
breast by the 5000cGy isodose line in red, just skimming at the edge
of the pectoralis muscle, yet limiting volume of lung irradiated.
energy photons may be a necessary component of the IMRT
treatment planning, to ensure adequate dose homogeneity.
To prevent radiation-induced heart disease resulting in
possibledeath15ormoreyearsafterthecompletionofbreast
cancer treatment, there is now signiﬁcant eﬀort made to
avoidtreatmentoftheheartafterBCS[67].Therearevarious
methods in the 3D era of radiation treatment planning to
avoid direct cardiac irradiation. The anterior lateral aspect
of the heart, including the left anterior descending artery,
can be very close to the posterior edge of the tangential
ﬁelds if treating the left breast. In some cases, changing
the gantry angle, the collimator angle or the posterior ﬁeld
border can exclude the heart from the radiation ﬁelds while
still providing coverage of the targeted segmental resection
site. In other cases, small cardiac blocks utilizing custom-
designed multileaf collimation can be placed to avoid cardiac
irradiation. In situations where the heart cannot be avoided
due to its proximity to the chest wall and surgical bed
in the free-breathing setting, a deep inspiration breath-
hold technique can be utilized. Planning is performed on
CT images obtained during the inspiratory phase of the
respiratory cycle, which displaces the heart both inferiorly
and medially, away from the left chest wall, and thus away
from the tangential beams of radiation [68]( Figure 4).
Prone positioning of the patient is another technique
that may be used in whole-breast irradiation. There are
several occasions where it may serve the patient better than
supine positioning. In general, the prone position allows the
breast and surgical bed to fall away from the chest wall.
As a result, more normal tissue can be excluded from the
tangential treatment ﬁelds, such as the heart, lung, and in
somecasestheribcage.Becauseofthemorelimitedposterior
coverage dosimetrically in the prone position, surgical beds
that lie close to the chest wall may not be optimally treated
in this position. Another advantage of the prone position is
to optimize treatment positing of a pendulous breast. The
pendulous breast hangs down above the treatment table,8 ISRN Oncology
(a) (b)
Figure 4: Deep inspiration breath-hold technique: notice how with deep inspiration the cardiac shadow has moved away from the chest
wall, allowing the radiation beams to adequately cover the breast and avoid direct irradiation of the heart.
thus avoiding skin folding in the inframammary fold and
axilla resulting in increased acute skin reactions. The width
of the breast is also reduced, reducing the beam energy
necessary for treatment and improving the homogeneity of
the treatment plan (Figure 5).
3.2. Accelerated Partial Breast Irradiation. Accelerated partial
breast irradiation (APBI) is attracting more attention from
both physicians and patients as an alternative to adjuvant
whole-breast irradiation in early stage breast cancer as the
eﬃcacy data continues to mature, suggesting similar in-
breast recurrence rates as whole breast irradiation [69–
71]. APBI targets the breast tissue immediately surrounding
the lumpectomy cavity; the breast tissue at highest risk of
harboring residual cancer cells. As a result, more normal
tissue, such as the rest of the breast tissue, rib cage, heart,
andlungisspared.Theoldesttechniqueofacceleratedpartial
breast irradiation is multicatheter interstitial brachytherapy.
Approximately 15 to 20 catheters are laid within and
immediately surrounding the segmental resection cavity,
treating approximately a 1.5cm margin of breast tissue away
from the edge of the cavity. When delivered with a high dose
rate iridium-192 source, a commonly used total dose and
fractionation schedule is 34Gy at 3.4Gy/fraction delivered
twice a day, six hours or greater apart for 10 fractions.
There is up to 10-year eﬃcacy and cosmetic data with
the multicatheter interstitial technique, some of which was
delivered as a low dose rate implant, noting low recurrence
rates in the breast, in general 5% or less, and similar to
whole-breast irradiation [71, 72]. Multicatheter interstitial
brachytherapy required expertise in needle placement, and
not all patients embraced the idea of multiple needles placed
through the breast. As a result, APBI with a brachytherapy
technique did not blossom until FDA approval of the
MammoSite device in 2002. A similar volume of breast
tissue is treated as compared to multicatheter interstitial
brachytherapy when treating to a volume 1cm around the
periphery of the MammoSite balloon when expanded within
the lumpectomy cavity [73, 74]. As ﬁve-year data has been
published in well-selected patients, again demonstrating low
recurrence rates in the breast treated with adjuvant APBI
with a MammoSite balloon applicator [69], interest emerged
in making APBI available to more women. The MammoSite
balloon’s simplicity of a single lumen device with a sin-
gle entry into the breast, as compared to multicatheter
brachytherapy, was also its limitation. Women with smaller
breast sizes and/or lumpectomy cavities that approached too
close to skin, within 5mm, were not able to be treated with a
MammoSite balloon, even if the tumor pathology and age
of the patient were compatible with APBI. We have now
seen come to market three other single-entry hybrid breast
brachytherapy devices that meld the simplicity of just one
entry site for the device, with the dosimetric versatility of the
multiple catheters in the ability to pull dose away from skin
and/or rib. The SAVI (Strut-Adjusted Volume Implant), the
Contura MLB (Multi-Lumen Balloon), and the MammoSite
ML (Multiple Lumen) all oﬀer a dosimetric improvement
in control over the original MammoSite (Figure 6). The
Contura MLB has four catheters oﬀset 5.5mm from the
central catheter, totaling ﬁve catheters. The balloon comes in
two sizes, 4.0–5.0cm and 4.5–6.0cm. At lower ﬁll volumes,
the Contura is somewhat elliptical in shape. At higher
ﬁll volumes, the balloon is more spherical. There are two
vacuum ports located at the distal and proximal ends of the
balloon. The vacuum port allows air and/or seroma to be
aspirated, that may have been separating the targeted breast
tissue away from the balloon. The MammoSite ML has three
catheters surrounding a central catheter, resulting in a total
of four catheters. The triad of catheters are oﬀset 3mm
from the central lumen. The diameter of the balloon is 4.0–
5.0cm. It is variable inﬂatable, similar to the Contura MLB.
The single lumen MammoSite balloons are also available
in diameters of spherical 4.0–5.0cm, spherical 5.0–6.0cm,
and an ellipsoidal balloon of 4.5–6.0cm. The SAVI device
is a multilumen single-entry breast brachytherapy device
without a balloon. The device comes in four sizes, rangingISRN Oncology 9
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Figure 5: Prone breast treatment positioning: notice the avoidance of the heart and the rib cage in the treatment ﬁelds. The prone position
has avoided the folding of the breast onto the upper abdominal skin, and thus reduced the dose delivered in the inframammary fold.
Figure 6: Single-entry hybrid breast brachytherapy catheters. Top:
MammoSite ML, middle: Contura MLB 4.0–5.0cm, and bottom:
SAVI 6-1 Mini.
from the 6-1 Mini SAVI to the 10-1 SAVI. The 6-1 Mini
measures 2.4cm × 5 c m .T h eS A V I1 0 - 1d e v i c em e a s u r e s
5cm × 7.5cm. The numbers represent the number of
catheters surrounding the central catheter. Therefore, the 6-
1 Mini has 6 catheters surrounding a central catheter. The
10-1 SAVI has 10 catheters surrounding a central catheter.
Additional sizes include the SAVI 6-1 and the SAVI 8-1. The
beneﬁt of these multiple breast brachytherapy device types
and sizes is more women who are candidates for APBI based
onageanddiseasepathologywillbeabletoreceiveAPBIwith
asingle-entrydeviceiftheychose.Thelimitationsofdistance
of lumpectomy cavity to skin surface and/or rib surface have
been signiﬁcantly reduced with these multilumen catheters.
The ability to maximize conformance of the device to the
lumpectomy cavity edge in all dimensions has also been
improved by the various sizes and shapes of the devices, and
in the case of the Contura MLB, by the vacuum ports.
To maximize the success of placement of the single-
entry brachytherapy device with excellent conformance, we
performed a limited noncontrast CT in our CT simulator up
to two days prior to planned placement of the device. Then
2D, 3D, and serial axial images may be sent electronically
to the breast surgeon, with discussion of cavity dimensions,
cavity volume, and minimum distance of the lumpectomy
cavity edge to skin surface and rib surface. The radiation
oncologist and breast surgeon can decide jointly which
device and size of device appears optimal for the individual
patient. The patient is then simulated for ﬁnal brachytherapy
treatment planning one to two days after placement of
the device. Given the dosimetric versatility of the multi-
l u m e nd e v i c e s ,w es t r i v ef o rV 9 5g r e a t e rt h a no re q u a lt o
95%, meaning 95% of the prescription dose is covering
greater than or equal to 95% of the planning target volume
for evaluation (PTV EVAL). The PTV EVAL is deﬁned as
the volume encompassed by a 1cm expansion around the
periphery of the device, limited to 5mm from skin surface
in the case of a balloon device, and 2mm from skin surface
in the case of the SAVI, and limited by posterior breast
tissue,whilesubtractingoutthelumpectomycavityvolume).
This coverage should take into account any nonconformance
of the device to breast tissue. In addition, we are able to
routinely limit the dose to skin, deﬁned as a 2mm rind of
tissue from skin surface into breast tissue) to under 115%
of dose to a 0.1cc volume, and often much lower. This is a
great improvement over the original limitation of a 145%
of prescribed dose to skin surface from the original single
lumen MammoSite [75]. In a similar fashion, we are able
to limit dose to the rib cage as well. As a result, we expect
acute and late toxicity of APBI with a single-entry device to
further improve even as we treat lumpectomy cavities that
were previously excluded due to proximity to rib or skin
(Figure 7).
Spacershavealsobeendevelopedtobeusedatthetimeof
surgeryatthediscretionoftheoperatingsurgeontoestablish
the tract and hold the cavity shape. After conﬁrmation that
the ﬁnal pathology is compatible for APBI, the spacer can
be removed and the ﬁnal catheter placed in the clinic. The
spacer alleviates the need for establishing the tract in the
clinic.
There are other noninvasive methods of APBI under-
going evaluation. They include 3D conformal radiother-
apy (3D-CRT), intensity-modulated radiotherapy (IMRT),
volumetric-modulated arc therapy (VMAT), and continu-
ous arc rotation of the couch (C-ARC) [76]. AccuBoost
is a noninvasive breast brachytherapy system which uses10 ISRN Oncology
Figure 7:SAVI10-1implant.Noticehowtheisodoselinespullaway
from the skin surface. The maximum dose to a 0.1cc volume of
skin is 101% of the prescribed 34Gy. The maximum dose to a 0.1cc
volume of rib is 100% of the prescribed 34Gy. There is excellent
dosimetric coverage of the PTV EVAL (V95 = 96% with only 0.9%
nonconformance).
mammographic localization and immobilization to direct
iridium-192 emissions along orthogonal axes [77]. APBI
utilizing multiple proton beams is also under investigation
[78].
It is an exciting time in breast radiation oncology, as
withadvancing technology westrive withimproved accuracy
to treat the targeted tissue potentially harboring residual
microscopic cancer cells, while minimizing dose to normal
tissues.
4. Conclusion
Thereisnoquestionforthosethattreatbreastcancerpatients
that a signiﬁcant proportion of time goes into counselling
the patient and family in terms of the various options
available to the patient for surgery and adjuvant treatments.
The practitioner should present all the options medically
relevant to the speciﬁc patient’s presentation and guide
the patient through the decision-making process so that
her ﬁnal decision best suits her circumstances and comfort
level. The data and technologic advances for optimization
of breast conservation are developing at lightning speed and
patient driven care and demands will likely continue the
push for state-of-art treatment, which will only contribute
to improved care of the breast cancer patient.
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